| 邱鸣磊,余苗,张卿,徐翠丽.NSCLC胸腔积液EGFR基因突变、肿瘤标记物水平及其预后观察.[J].中南医学科学杂志.,2024,(5):796-799. |
| NSCLC胸腔积液EGFR基因突变、肿瘤标记物水平及其预后观察 |
| Observation of EGFR gene mutations, tumor marker levels in pleural effusion, and prognosis of NSCLC |
| 投稿时间：2024-06-05 修订日期：2024-08-21 |
| DOI：10.15972/j.cnki.43-1509/r.2024.05.026 |
| 中文关键词: 非小细胞肺癌 胸腔积液 表皮生长因子受体 基因突变 预后 |
| 英文关键词:NSCLC thoracic effusion EGFR genetic mutations prognosis |
| 基金项目:无锡市卫生健康委科研项目(Q202136) |
|
| 摘要点击次数: 162 |
| 全文下载次数: 118 |
| 中文摘要: |
| 目的观察非小细胞肺癌(NSCLC)患者胸腔积液中表皮生长因子受体(EGFR)基因突变检出率、肿瘤标记物水平及其预后。 方法选取本院接受治疗的117例晚期NSCLC合并胸腔积液患者作为研究对象,根据患者治疗前胸腔积液的EGFR基因突变检测结果分为EGFR突变型(突变组)与未突变型(野生组)。突变组患者接受酪氨酸激酶抑制剂(TKI)治疗,野生组患者接受常规化疗。比较两组肿瘤标志物水平、临床病理学特征、近期疗效及预后结局。 结果117例NSCLC患者中47例发生EGFR突变,突变率为40.17%。与野生组比较,突变组血清癌胚抗原(CEA)水平以及腺癌、TNM分期Ⅳ期占比升高(P＜0.05),糖类抗原125(CA125)、鳞状细胞癌抗原(SCCA)、细胞角蛋白19(CYFRA21-1)水平以及吸烟、低分化程度占比降低(P＜0.05)。突变组患者总疗效优于野生组(P＜0.05)；生存率高于野生组(P＜0.05)；中位生存时间长于野生组(P＜0.05)。 结论EGFR突变型NSCLC患者的血清CEA水平高于野生型,CA125、SCCA、CYFRA21-1水平低于野生型,同时突变型患者采用TKI治疗的近期疗效及预后优于接受常规化疗的野生型患者。 |
| 英文摘要: |
| AimTo observe the detection rate of epidermal growth factor receptor (EGFR) gene mutations, tumor marker levels in pleural effusion, and prognosis of non-small cell lung cancer (NSCLC) patients. Methods117 patients with advanced NSCLC complicated with pleural effusion who received treatment in our hospital were selected as the research subjects. The patients were divided into EGFR mutant group (mutant group) and non-mutant group (wild-type group) according to the EGFR gene mutation detection results of the pleural effusion before treatment. Patients in the mutant group received tyrosine kinase inhibitor (TKI) treatment, while patients in the wild-type group received conventional chemotherapy. The levels of tumor markers, clinical and pathological characteristics, short-term efficacy, and prognosis outcomes in two groups were compared. ResultsAmong 117 NSCLC patients, 47 patients developed EGFR mutations, with a mutation rate of 40.17%. Compared with the wild-type group, the serum carcino-embryonic antigen (CEA) level and the proportion of adenocarcinoma and TNM stage Ⅳ were increased in the mutant group (P＜0.05), and the levels of carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCCA), cytokeratin 19 fragment (CYFRA21-1), the proportion of smoking and low differentiation were decreased in the mutant group (P＜0.05). The overall therapeutic effect of mutant group was better than that of wild-type group (P＜0.05). The survival rate of patients in the mutant group was higher than that in the wild-type group (P＜0.05). The median survival time of the mutant group was longer than that of the wild-type group (P＜0.05). ConclusionThe serum CEA levels of EGFR mutant NSCLC patients are higher than those of wild-type patients, while CA125, SCCA, and CYFRA21-1 levels are lower than those of wild-type patients.At the same time, the short-term efficacy and prognosis of TKI treatment in mutant patients are better than those in wild-type patients receiving conventional chemotherapy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|